Answers are grounded in this paper and cite their sources.
Background Non-alcoholic fatty liver disease (NAFLD) has emerged as a global public health burden with an exponential rise in prevalence, encompassing a spectrum of pathological conditions from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. The asymptomatic nature of early-stage NAFLD leads to substantial delays in clinical intervention, as conventional diagnostic modalities lack sufficient sensitivity and specificity for early detection. Objective This review aims to systematically summarize the application of proteomics in the discovery of non-invasive diagnostic biomarkers for early-stage NAFLD, with a focus on core technological platforms, validated protein biomarkers from diverse biological matrices, and key translational obstacles. Methods A comprehensive literature search and critical evaluation of peer-reviewed studies on proteomic technologies and their application in NAFLD biomarker discovery was performed. The review covers mass spectrometry-based platforms, protein arrays, and emerging high-throughput methodologies, as well as biomarker candidates derived from serum, hepatic tissue, and exosomes. Results Proteomic technologies have significantly advanced the identification of candidate biomarkers for early NAFLD diagnosis. Several protein biomarkers from diverse biological matrices have shown promise in distinguishing simple steatosis from NASH and in reflecting disease progression. However, substantial challenges remain in biomarker validation, standardization of analytical workflows, and translation to clinical practice. Additionally, emerging ethical frameworks are increasingly recognized as essential components of proteomic biomarker research. Conclusion Proteomics offers powerful tools for early NAFLD biomarker discovery, yet the transition from discovery to clinical implementation requires addressing validation, standardization, and ethical challenges. This review provides a systematic overview to facilitate the translation of proteomic biomarkers into clinical practice and enhance the early screening and prognosis of NAFLD.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: